Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy

© 2015 American Association for Cancer Research. Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study. Experimental Design: Patients were...

Saved in:

書目詳細資料
Main Authors:	Tony Mok, Yi Long Wu, Jin Soo Lee, Chong Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, Lin Wu
格式:	雜誌
出版:	2018
主題:	Agricultural and Biological Sciences
在線閱讀:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84938399710&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/44286
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!
機構:	Chiang Mai University

相似書籍

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
由: Tony Mok, et al.
出版: (2018)

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
由: Tony Mok, et al.
出版: (2018)

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
由: Mok T., et al.
出版: (2017)

The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable nonmetastasis NSCLC as a prognostic marker of disease
由: Virote Sriuranpong
出版: (2010)

Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer
由: Tony S. Mok, et al.
出版: (2018)

Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer
由: Tony S. Mok, et al.
出版: (2018)

Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer
由: Mok T.S., et al.
出版: (2014)

Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedules
由: Sutiman N., et al.
出版: (2019)

Erlotinib in previously treated non-small-cell lung cancer
由: Frances A. Shepherd, et al.
出版: (2018)

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial
由: Giorgio V. Scagliotti, et al.
出版: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Chee Khoon Lee, et al.
出版: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Chee Khoon Lee, et al.
出版: (2018)

Evaluation dose-response characteristics of megestrol acetate in Thai patients with cancer anorexia-cachexia
由: Virote Sriuranpong
出版: (1996)

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
由: Scagliotti G.V., et al.
出版: (2014)

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
由: Byoung Chul Cho, et al.
出版: (2018)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
由: Wong, A.S., et al.
出版: (2014)

Management of NSCLC: The Era of Immunotherapy
由: Laksmi Wulandari, -
出版: (2019)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
由: Afrita Amalia Laitupa, -, et al.
出版: (2019)

Serum concentrations of erlotinib at a dose of 25 mg daily
由: Costa, D.B., et al.
出版: (2014)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
由: Suresh S. Ramalingam, et al.
出版: (2020)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
由: Suresh S. Ramalingam, et al.
出版: (2020)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
由: Sumitra Thongprasert, et al.
出版: (2018)

Treatment Strategies in ALK-Positive NSCLC
由: Laksmi Wulandari, -
出版: (2019)

Phase II study of concurrent chemoradiotherapy for inoperable (Bulky) stage III (A/B) Non-Small Cell Lung Cancer (NSCLC) : A preliminary report
由: Vorachai Ratanatharathorn, et al.
出版: (2018)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
由: Natthaporn Sueangoen, et al.
出版: (2020)

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
由: Sith Sathornsumetee, et al.
出版: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Lee C., et al.
出版: (2017)

Clinical Benefit of EGFR-TKI in Management of NSCLC
由: Siprianus Ugroseno Yudho Bintoro
出版: (2017)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
由: Goh, Kah Yee, et al.
出版: (2024)

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma
由: David A. Reardon, et al.
出版: (2018)

Lithium intercalation into bilayer graphene
由: Ji, K, et al.
出版: (2020)

The Role and Benefit of Pemetrexeed in The First Line Treatment of NSCLC
由: Siprianus Ugroseno Yudho Bintoro
出版: (2017)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Cetyltrimethylammonium bromide intercalated graphene/polypyrrole nanowire composites for high performance supercapacitor electrode
由: Mao, L., et al.
出版: (2014)

CLINICAL AND FUNCTIONAL SIGNIFICANCE OF CD151 IN WILDTYPE EGRF NSCLC
由: WONG HUEE PING AMANDA
出版: (2020)

Ion-selective detection of non-intercalating Na+ using competitive inhibition of K+ intercalation in Prussian blue nanotubes sensor
由: Ang, J.Q., et al.
出版: (2014)

Surfactant-intercalated, chemically reduced graphene oxide for high performance supercapacitor electrodes
由: Zhang, K., et al.
出版: (2014)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
由: Yeo, W.-L., et al.
出版: (2011)

EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter
由: Voon, P.J., et al.
出版: (2014)